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Oral mucosa: an alternative epidermic 
cell source to develop autologous 
dermal-epidermal substitutes from 
diabetic subjects
Oral mucosa has been highlighted as a suitable source of epidermal cells 
due to its intrinsic characteristics such as its higher proliferation rate and its 
obtainability. Diabetic ulcers have a worldwide prevalence that is variable 
(1%-11%), meanwhile treatment of this has been proven ineffective. Tissue-
engineered skin plays an important role in wound care focusing on strategies 
such autologous dermal-epidermal substitutes. Objective: The aim of this 
study was to obtain autologous dermal-epidermal skin substitutes from oral 
PXFRVD IURPGLDEHWLF VXEMHFWV DV D ¿UVW VWHS WRZDUGV D SRVVLEOH FOLQLFDO
application for cases of diabetic foot. Material and Methods: Oral mucosa was 
obtained from diabetic and healthy subjects (n=20 per group). Epidermal 
FHOOVZHUHLVRODWHGDQGFXOWXUHGXVLQJDXWRORJRXV¿EULQWRGHYHORSGHUPDO
epidermal in vitro substitutes by the air-liquid technique with autologous 
human serum as a supplement media. Substitutes were immunocharacterized 
ZLWKFROODJHQ,9DQGF\WRNHUDWLQDVVSHFL¿FPDUNHUV$6WXGHQWVWWHVW
was performed to assess the differences between both groups. Results: It 
was possible to isolate epidermal cells from the oral mucosa of diabetic and 
healthy subjects and develop autologous dermal-epidermal skin substitutes 
using autologous serum as a supplement. Differences in the expression 
RI VSHFL¿FPDUNHUVZHUH REVHUYHG DQG WKH F\WRNHUDWLQ  H[SUHVVLRQ
was lower in the diabetic substitutes, and the collagen IV expression was 
higher in the diabetic substitutes when compared with the healthy group, 
VKRZLQJDVLJQL¿FDQWGLIIHUHQFH&RQFOXVLRQ&HOOVIURPRUDOPXFRVDFRXOG
be an alternative and less invasive source for skin substitutes and wound 
healing. A difference in collagen production of diabetic cells suggests diabetic 
substitutes could improve diabetic wound healing. More research is needed 
to determine the crosstalk between components of these skin substitutes 
and damaged tissues.
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Introduction
$GYDQFHPHQWV LQ WKH ¿HOG RI WLVVXH HQJLQHHULQJ
have allowed the widespread use of skin substitutes 
to cover wounds and to promote healing19. Great 
progress has been achieved in the culturing of 
NHUDWLQRF\WHVDQG¿EUREODVWVWKLVKDVEHHQHVSHFLDOO\
true for keratinocytes since the first successful 
culture by Rheinwald and Green in 197525, to the 
present day, with the creation of specialized in 
vitro techniques14,22,23,24. Although current tissue-
engineered skin substitutes have shown promising 
results for wound healing6,8,11,13,26, there are still 
several challenges to overcome, therefore there is a 
continuing search for novel approaches to wound care 
and treatments that could be more effective, where 
all epidermal cells and matrices are obtained from the 
same patient, with less invasive sources to obtain the 
biological components, and with new alternatives to 
harvest tissue in patients with physiological and ethical 
limitations due to their conditions.
Oral mucosa has been highlighted as a viable 
alternative source of epidermal cells, due to its easy 
preparation and suitable features, such as higher cell 
proliferation rates, lower terminal cell differentiation 
degrees and an increased biological activity compared 
with epidermal keratinocytes22. This tissue also has 
the advantage that its harvesting produces less 
disability, and provides better aesthetic outcomes. 
With these special features, it is assumed that the 
skin substitute obtained from oral mucosa can be 
produced faster. A possible disadvantage for the use of 
oral mucosa as an epidermal cell source could be the 
differentiation of the epithelial pattern of keratinocytes 
from oral mucosa, which differs from that of epidermal 
keratinocytes and skin. The skin is an example of an 
orthokeratinized epithelium. It displays a stratum 
basale, stratum spinosum, stratum granulosum and 
stratum corneum. Gingiva tissue also consists of an 
epithelium on a connective tissue matrix populated 
PDLQO\ZLWK¿EUREODVWVDQGHQGRWKHOLDOFHOOVKRZHYHU
in contrast to skin, the epithelium is parakeratinized27. 
In this regard, Ueda, et al.26 (1995) reported in their 
study that a grafted sheet of keratinocytes from 
oral mucosa changed the epithelial pattern over a 
period of 4 weeks, explaining this phenomenon due 
to epithelial-mesenchymal interactions, suggesting 
WKDWWKHVSHFL¿FLW\RIWKHHSLWKHOLXPLVGHSHQGHQWRQ
WKHLQÀXHQFHRIWKHXQGHUO\LQJPHVHQFK\PDOWLVVXH
Worldwide, diabetic foot is a major medical, 
social and economic problem. It is estimated that 
approximately 15% of the more than 150 million 
people with diabetes world-wide will at some stage 
develop diabetic foot ulceration7. Foot problems are 
indeed a global problem and there is no area in the 
world that does not report the development of foot 
lesions as a consequence, mainly of neuropathy and 
peripheral vascular disease. The prevalence of active 
foot ulceration varies from approximately 1% in certain 
European and North American studies to more than 
11% in reports from some African countries7. Although 
there have been many developments in recent years, 
which encourages optimism for future improvement 
in diabetic foot care, there is still much to be done.
The aim of the present study was to obtain an 
autologous dermal-epidermal skin substitute using 
oral mucosa tissue from diabetic subjects with a 
PHDVXUDEOHLPPXQRÀXRUHVFHQFHFKDUDFWHUL]DWLRQDVD
¿UVWVWHSWRSHUIHFWLQJWKHGHYHORSPHQWWHFKQLTXHZLWK
the main focus of future possible clinical applications 
on the treatment of diabetic foot ulcers. Also it 
SURSRVHVIRUWKH¿UVWWLPHPDLQWDLQLQJWKLVVXEVWLWXWH
using autologous serum, thus avoiding the use of 
animal products and promoting the development of 
the construct.
Material and methods
This was an experimental in vitro test carried out 
at Hospital Central “Dr. Ignacio Morones Prieto”, the 
Basic Sciences Laboratory, Faculty of Stomatology, 
Universidad Autónoma de San Luis Potosí. The study 
was performed in accordance with the Helsinki 
Declaration, and it was approved by the Faculty’s 
Ethical Board (CEIFE-033-012).
Subjects
Twenty adult subjects with diabetes mellitus 
type II (DM2), diagnosed according to the American 
Diabetics Association guidelines16, and 20 healthy 
controls donated 20 ml of peripheral blood and a 
sample of oral mucosa from the retromolar area. 
Blood was collected in labeled Vacutainer tubes, 10 ml 
without additives, and 10 ml with sodium citrate (BD 
Vacutainer®, Franklin Lakes, NJ, USA)  and frozen at 
20°C, until used. Oral mucosa samples were obtained 
with a 3 mm biopsy punch (Miltex, Davies Drive York, 
PA, USA) previous aseptic and antiseptic controls and 
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inferior alveolar nerve blockage (IAN). Hemorrhage 
was controlled by direct means for 10 minutes. 
Patients received instructions for wound care, and a 
follow-up after 7 days. None of the patients presented 
complications.
Isolation and cell culture
Each oral mucosa sample was collected in 1.5 ml 
tubes containing phosphate buffered saline (PBS), 
 ǋJPO VWUHSWRP\FLQ  ,8PO SHQLFLOOLQ DQG
ǋJPODPSKRWHULFLQ%DOOIURP6LJPD$OGULFKSt. 
Louis, MO, USA) and preserved at 4°C for 12 h. Oral 
mucosa was macroscopically separated by region, with 
a scalpel, into epithelium and connective tissue. By 
using the explant technique, each region was grown 
separately in 25 cm2 culture dishes (Nunc, Roskilde, 
Denmark). DMEM low glucose medium (Sigma-Aldrich, 
St. Louis, MO,USA) supplemented with 10% fetal 
calf serum (Sigma-Aldrich, St. Louis, MO, USA) was 
XVHGDVFXOWXUHPHGLXPIRU¿EUREODVWV.HUDWLQRF\WHV
ZHUH FXOWXUHGXVLQJ41PHGLXP D VSHFL¿F FXOWXUH
medium for keratinocytes). After 3 days the fetal calf 
serum concentration was reduced to 5%, and after a 
further 3 days to 1%. Blood samples were defrosted 
and centrifuged at 1200 rpm for 10 minutes. Serum 
and plasma were isolated and kept at -20°C until use. 
Autolougus serum was used for cell culture instead of 
the fetal calf serum after 7 days, while the plasma was 
used to develop the stroma for the substitutes. Both 
cell lines were incubated at 37°C in an atmosphere 
of 5% CO2XQWLOWKHFXOWXUHVUHDFKHGDFRQÀXHQFHRI
80%. The culture media was changed every third day.
Cell cultures characterization
2QFHWKHFXOWXUHVUHDFKHGDFRQÀXHQFHRI
part of the cell cultures were used for an indirect 
LPPXQRÀXRUHVFHQFHDVVHVVPHQW,QRUGHUWRDVVXUH
WKDWWKHFHOOVZHUH¿EUREODVWVDQGNHUDWLQRF\WHVWKH
characterization of these cell cultures was performed. 
7KHVSHFL¿FPRQRFORQDODQWLERG\XVHGIRU¿EUREODVWV
was anti-collagen I (Santa Cruz Biotechnology, Paso 
Robles, CA, USA) mainly because due to its abundance 
in the skin, recognized as the most abundant collagen 
LQWKHHSLGHUPLVDQGLWVVSHFL¿FLW\IRUWKLVFHOOW\SH
For keratinocyte was anti-cytokeratins 5-14 (Santa 
Cruz Biotechnology, Paso Robles, CA, USA). As 
VHFRQGDU\ DQWLERGLHV $OH[D ÀXRU  $QWL5DEELW
IgG polyclonal, Invitrogen, Waltham, MA, USA) and 
Alexa 594 (Anti-mouse monoclonal IgG, Invitrogen, 
:DOWKDP0$86$ZHUHDOVRXVHG%ULHÀ\FHOOVZHUH
grown on round glass cover slips (12 mm). After 12 h 
RILQFXEDWLRQWKHFXOWXUHVZHUH¿[HGIRUPLQXWHV
with neutral formalin, permeabilized with Triton 
X100 0.025% for 20 min at room temperature then 
blocked with bovine serum albumina (BSA) 1% for 
45 min. The primary antibodies were incubated for 2 
h at room temperature and the secondary antibodies 
were incubated for 2 h at room temperature and were 
protected from light. Between each step, phosphate 
buffered saline rinses were made. The samples 
were observed by confocal microscopy (Leica, Model 
DMI4000B, Wetzlar,Germany) and LASAF® software 
(Leica, Wetzlar, Germany).
Development of the dermo-epidermal substitute
Stromal phase
Fibroblasts were detached from culture dishes 
using TrypLE Express (Invitrogen, Waltham, MA, USA), 
centrifuged and suspended once more in the medium 
DQGTXDQWL¿HGE\2QH6FHSWHU0LOOLSRUH%LOOHULFD0$
USA). Cells were again suspended in DMEM low glucose 
medium (Sigma-Aldrich, St. Louis, MO, USA) with 1% 
of human serum obtained from each subject, reaching 
a cell concentration of 500,000 per 1 mL. A solution 
was made by mixing the resuspended cells with plasma 
DQGDJDURVHDWWRFUHDWH¿EULQDJDURVHJHOV5. 300 
microliters of the solution were placed in the Transwell 
system (Corning, Midland, NC, USA) following the air-
liquid technique3. Culture medium was placed covering 
the entire substitute. Each system was incubated at 
37°C in a 5% CO2 atmosphere and with a  relative 
humidity of 95% for 10 days (Figure 1a, b).
Epithelial phase
Cultured keratinocytes were detached from the 
culture dishes using TrypLE Express (Invitrogen, 
Waltham, MA, USA), centrifuged and resuspended in 
a QN medium with 1% human serum obtained from, 
DQG TXDQWL¿HG E\2QH 6FHSWHU 0LOOLSRUH %LOOHULFD
MA, USA) to reach a concentration of approximately 
500,000 cells per 1 mL. One hundred microliters of 
the cell solution were placed in the Transwell system 
(Corning, Midland, NC, USA) on the top of the already 
set stroma, and incubated for 10 days using the air-
liquid technique. Culture medium was placed covering 
ERWKFRPSDUWPHQWVRQWKH¿UVWGD\RIVHWWOHPHQWRQ
the fourth day, the culture medium was placed only in 
the lower compartment. Each system was incubated 
at 37°C in a 5% CO2 atmosphere with a  95% relative 
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humidity for 10 further days.
Dermal-epidermal substitute evaluation and 
characterization
Substitutes were mechanically separated from each 
system and placed in dishes with 1X PBS to remove 
H[FHVVRIWKHPHGLXP6XEVHTXHQWO\WKH\ZHUH¿[HG
with 4% paraformaldehyde and placed in a solution 
of 3% sucrose as a cryoprotector. Cryosections of 6 
microns thickness were made at -29°C in a cryostat 
(Leica Model CM1510S-3, Wetzlar, Germany). From 
each sample, 100 cuts were made and placed on 50 
slides (two cuts per slide). Each slide was treated for 
LWVLQGLUHFWLPPXQRÀXRUHVFHQFHDVVHVVPHQW
For the characterization of these dermal-epidermal 
VXEVWLWXWHVWKHVSHFL¿FPRQRFORQDODQWLERGLHVXVHG
were anti-collagen IV and anticytokeratins 5-14 (Santa 
Cruz Biotechnology, Paso Robles, CA, USA). Collagen 
IV was assessed in this characterization due to its 
role as the primary collagen found in the extracellular 
basal membranes separating a variety of epithelial 
and endothelial cells. It is a major component of the 
dermal-epidermal junction, where it is mostly found in 
the lamina densa of the basal membrane9. The basal 
membrane zone mediates tissue compartmentalization 
and sends signals to epithelial cells about the external 
microenvironment, and also has important structural 
and functional effects on blood vessels, constituting an 
extracellular microenvironment sensor for endothelial 
cells and pericytes9. Meanwhile, Cytokeratins 5-14 
(CK5-14) are expressed on basal keratinocytes and 
WKHH[SUHVVLRQRIWKHVH¿ODPHQWVDUHFKDUDFWHULVWLFRI
FRPSOH[VWUDWL¿HGHSLWKHOLD1. Keratin 14 (CK14) is a 
prototypic marker of dividing basal keratinocytes and 
helps in the maintenance of epidermal cell shape; 
it also provides resistance to mechanical stress. 
Interestingly, the CK5/CK14 pair is expressed in the 
basal layer of the epidermis, which contains epidermal 
stem cells and transient amplifying (TA) cells2. 
0RQRFORQDOVHFRQGDU\DQWLERGLHV$OH[DÀXRUDQG
594 (Invitrogen, Waltham, MA, USA) were also used. 
7HQGLIIHUHQW¿HOGVZHUHFKRVHQUDQGRPO\IURPHDFK
slide; each slide of every substitute created to be 
evaluated, was chosen by the sample function of the 
R program, version 3.0.1. The evaluation of the slide 
was performed by an observer blinded to the nature 
of the study. A total of 20 images were obtained; 
observations were performed by confocal microscopy 
(Leica, Model DMI4000B, Wetzlar, Germany) and the 
LASAF® software (Leica, Wetzlar, Germany). Images 
obtained were evaluated by Image J program manager 
(1.46a version, NIH) with the ROI function getting the 
PHDQRIWKHDUELWUDU\ÀXRUHVFHQFHXQLWVper slide, per 
antibody for further statistical analysis.
Cell growth curve
Cell growth curves were performed (N=8). Cultures 
of 4 healthy subjects and 4 age-matched diabetic 
subjects were selected. Fibroblasts were subculture in 
duplicate in 6 well boxes by placing 100,000 cells per 
well. The evaluation times were 0, 3, 6 and 9 days.
Statistics
Statistical analysis at 95% of confidence was 
performed using JMP 8 software (SAS Institute Inc., 
Cary, NC, USA) and R 3.1.320. An analysis of descriptive 
statistics, obtaining the measures of a central tendency 
and dispersion of all the variables was then performed. 
For the bivariate comparative analysis we used the 
Student’s t-test for continuous variables based on 
a normal distribution calculated with plot of Fox10. 
For categorical variables the Chi-squared test was 
applied. A paired Student´s t test for time 0 versus 
3, 6 and 9 days for the growing cellularity between 
WKHJURXSVZDVSHUIRUPHG6WDWLVWLFDOVLJQL¿FDQFHZDV
considered with a p value <0.05. For the cell growth 
FXUYHVWDWLVWLFDOVLJQL¿FDQFHZDVFRQVLGHUHGZLWKD
Bonferroni correction of alpha for 3 comparisons with 
a p value of <0.016.
Figure 1- $$LUOLTXLGWHFKQLTXHSKDVH'HYHORSPHQWRIVWURPDZLWKWKH¿EULQDJDURVHJHOV%6SHFL¿FFXOWXUHPHGLXPSODFHGLQD
Transwell System in accordance with the air-liquid technique
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Results
Study demographics
A total of 40 oral mucosa samples were collected 
(n=20 per group) according to the previously set 
criteria. Of the total of samples taken, 19 corresponded 
to men and 21 to women. The average age was 
52.15±13.5 years. Variables studied in each group are 
showed in Table 1. Characteristics including age and 
sex were relatively homogenous between both groups.
Obtaining and characterization of cell cultures
Fibroblast and keratinocyte cultures were 
established from the oral mucosa from diabetic 
and healthy subjects (Figure 2a, b). Cell cultures 
achieved 80% percent of confluence at different 
times; diabetic cultures had a culture day average of 
25.3±3.09, meanwhile the healthy subjects’ culture 
day average was 26.85±1.78. Cell morphology showed 
by cultures of the two cell lines corresponded to the 
W\SLFDOPRUSKRORJ\RI¿EUREODVWVDQGNHUDWLQRF\WHV
Fibroblast´ cultures were positive for anti-collagen 
I, and keratinocyte cultures were positive for anti-
cytokeratins 5 and 14 (Figure 2c, d).
Cell growth curve
Cell proliferation results showed a significant 
increased growth in the diabetic group at time 0 vs 
3 days (p=0.009), and time 0 vs 9 days (p=0.004); 
KRZHYHU VWDWLVWLFDOO\ ZLGH FRQ¿GHQFH LQWHUYDOV DUH
DIABETIC SUBJECTS GROUP 
(N=20)
HEALTHY SUBJECTS GROUP
(N=20) 
P VALUE
Age 57.55*±11.59† 47*±15.92† 0.75‡
Sex (M/F) 9/11 10/10 0.02§
Culture days 25.3*±3.09† 26.85*±1.78† 0.05‡
AFU Col-IV 8.05*±1.59† 6.15*±3.16† 0.02‡
AFU Ck 5-14 9.56*±3.741† 10.47*±5.86† 0.05‡
AFU Total 17.61*±5.22† 16.62*±8.94† 0.67‡
*Mean
†Standard deviation
‡ Student´s t-test
§Chi-Square
Match paired Student´s T-test
Table 1- Studied variables per group
Figure 2-$)LEUREODVWFXOWXUHDWFRQÀXHQFH%.HUDWLQRF\WHFXOWXUHDWFRQÀXHQFH&3RVLWLYHLPPXQRÀXRUHVFHQFHIRU¿EUREODVWVDQWL
FROODJHQ,'3RVLWLYHLPPXQRÀXRUHVFHQFHIRUNHUDWLQRF\WHVDQWLF\WRNHUDWLQ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showed, indicating greater variability in the behavior 
of the diabetic group compared with the healthy group 
(Figure 3, Table 2).
Development of the dermo-epidermal substitute
Substitutes were developed using the air-liquid 
technique, as previously described. The culture time 
for the stromal and epithelial phase was 10 days for 
each. Once both phases were completed, diabetic and 
healthy substitutes were observed with an inverted 
microscope at 40X, showing interesting features. 
$Q H[WHQGHG FHOOXODU SDWWHUQZLWKPRUH ¿EHUVZDV
observed in the diabetic substitutes, whereas healthy 
substitutes showed a globular pattern with fewer 
¿EHUV)LJXUHDE7KHFOLQLFDODSSHDUDQFHRIWKH
substitutes was clear and humid with an adherence 
to surfaces (Figure 5).
Dermal-epidermal substitute evaluation and 
characterization
Each substitute was characterized and assessed as 
previously described. Anti-cytokeratin 5-14 expression 
showed 1.14 DUELWUDU\ÀXRUHVFHQFHXQLWVAFU) less 
in the diabetic substitutes compared with the healthy 
control group. Anti-collagen IV expression was 1.9 
AFU higher in the diabetic substitutes when compared 
with the healthy group. In addition, dermo-epidermal 
skin substitutes were immunostained with Sytox Red 
(Invitrogen, Waltham, MA, USA) showing the nucleus 
and the cytoskeleton was stained with Phalloidin 
DIABETIC SUBJECTS GROUP
(N=4)
HEALTHY SUBJECTS GROUP
(N=4)
P VALUE
Basal 100.000 100.000 1‡
Day 3 409,999*±258,686† 257,500*±20615† 0.009||
Day 6 1’089,999*±991,407† 585,000*±123693† 0.02||
Day 9 1’305,000*±1’075,648† 1’005,000*±185022† 0.004||
*Mean
†Standard deviation
‡ Student´s t-test 
§ Chi-Square
||Match paired Student´s T-test
Table 2- Cell proliferation at the growth cell curve
Figure 3-&HOOJURZWKFXUYH&HOOSUROLIHUDWLRQRIWKH¿EUREODVWVRIGLDEHWLFVVXEMHFWVYVKHDOWK\VXEMHFWVDIWHUGD\VRILQFXEDWLRQ'LDEHWLF
subjects (green) had an increased cell proliferation since day 3 in comparison with healthy subjects (red)
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(Invitrogen, Waltham, MA, USA), showing the cell 
distribution throughout the thickness of the substitute 
(Figure 6).
Statistical analysis
A Student’s T-test was performed as planned. All 
variables showed a normal distribution. There was a 
VLJQL¿FDQWGLIIHUHQFHEHWZHHQWKHGLDEHWLFJURXSDQG
the healthy group for DUELWUDU\ÀXRUHVFHQFHXQLWVRI
collagen IV (AFU col-IV) p value=0.02 and arbitrary 
ÀXRUHVFHQFHXQLWVRIF\WRNHUDWLQAFU ck 5-14) 
p value=0.05 (Table 1).
Discussion
Skin tissue engineering is a therapeutic field 
developed to aid in the healing of injured skin, 
HVSHFLDOO\IRUZRXQGVWKDWKDYHGLI¿FXOW\KHDOLQJ LQ
the primary stage. This study showed the development 
of the dermo-epidermal substitutes of oral mucosa 
obtained from the retromolar area with a 3 mm 
punch biopsy from diabetic and healthy subjects, 
using the air-liquid technique and its assessment by 
LPPXQRÀXRUHVFHQFH FKDUDFWHUL]LQJ DQG TXDQWLI\LQJ
LWVLQWHQVLW\LQ$)8DVD¿UVWVWHSWRZDUGVDSRVVLEOH
future clinical application. Recent studies show 
oral mucosa to be a feasible, alternative source of 
epidermal cells and matrices, mainly for its intrinsic 
characteristics studied and described in previous 
studies. Iida, et al.13 (2005) developed an epidermal 
equivalent from oral mucosa based on an acellular 
allogeneic dermal matrix showing good results after 
its clinical application13,26. Other studies reported the 
development of skin substitutes using cells obtained 
from biopsies of human skin, mainly the foreskins of 
children or from established epidermal cell lines. The 
main disadvantage of this approach is the allogeneic 
nature of the cells and the latent possibility of short-
term rejection by the host. Still, wound healing was 
accomplished with its clinical application6,8,11.
Figure 4- A. Dermal-epidermal substitutes of healthy subjects observed under the inverted microscope (40X). A globular pattern is 
REVHUYHG%'HUPDOHSLGHUPDOVXEVWLWXWHVRIGLDEHWLFVXEMHFWVREVHUYHGXQGHUWKHLQYHUWHGPLFURVFRSH;$¿EULOODUSDWWHUQLVREVHUYHG
Figure 5- Clinical appearance of the developed dermal-epidermal skin substitute
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3ULPDU\FXOWXUHVRI¿EUREODVWVDQGNHUDWLQRF\WHV
were achieved from both populations (diabetic and 
healthy subjects) by the explant technique. Eighty 
SHUFHQW RI FRQÀXHQFH ZDV DFKLHYHG LQ  GD\V
for diabetic subjects and for healthy subjects in 
26.85 days. In similar studies, the production of 
SULPDU\¿EUREODVWDQGNHUDWLQRF\WHFXOWXUHVKDVEHHQ
reported by the explant technique alone8, and also 
using enzymatic techniques such as cell disruption 
without mentioning the time at which they achieved 
confluence, pointing out only the use of cells in 
different culture passages11,13,24. In primary cell culture 
techniques, cell disintegration is a strategy that can 
reduce culture times up to 50%, yet has the main 
disadvantage of the possibility of damaging tissues and 
cells12. It is important to point out that for the clinical 
application of these skin dermal-epidermal substitutes, 
cell culture times should be reduced, and thereby the 
enzymatic digestion technique is a good strategy to 
be used for future studies.
Regarding the development of dermo-epidermal 
VXEVWLWXWHVWKHDLUOLTXLGWHFKQLTXHZDVDQHI¿FLHQWFHOO
culture technique for obtaining these skin equivalents. 
It provides the conditions and characteristics needed 
for the obtention of this kind of tissue, mainly by the 
gas exchange (CO2 and O2) of the epithelial layer in 
WKH¿QDOVWDJH,WDOORZVIRUDSODFHVSHFL¿FFXOWXUH
PHGLXPIRUHDFKFHOOOLQH¿EUREODVWVDQGPDWULFHVLQ
the lower compartment and keratinocytes in the upper 
compartment) throughout the entire culture process20. 
In our study, the construct remained intact throughout 
the in vitro process, allowing for the manipulation of 
both compartments independently compared with 
other culture techniques and materials11,21,22,24. Culture 
times reported through the air-liquid technique range 
from day 1 of the stromal stage, up to 5 days, and 
the epithelial phase for a period of 5 to 10 days21. In 
this study we used 10 days in the cultures for both 
phases; stromal and epithelial, obtaining good results 
in relation to the establishment of the stromal cells 
DVHYLGHQFHGE\WKHLPPXQRÀXRUHVFHQFHHYDOXDWLRQ
In the assessment of the substitutes by 
LPPXQRÀXRUHVFHQFHWKHUHZDVDVLJQL¿FDQWGLIIHUHQFH
observed between both groups (p=0.002 for AFU COL-
IV and p=0.05 for AFU CK5-14). The results showed 
OHVVDUELWUDU\ÀXRUHVFHQFHXQLWVIRUNHUDWLQRF\WHV&.
14 antibody) in the substitutes generated from the oral 
mucosa of diabetic subjects (9.56) compared to those 
generated from the oral mucosa of the healthy subjects 
(10.47). In relation to the above, recent studies show 
an association of Neurotensin (NT), a neurotransmitter 
involved in the process of wound healing. Moura, et 
al.15 (2014) studied the effects of neurotensin on 
human keratinocytes under hyperglycemic conditions 
and normal conditions at different functional levels, 
mainly NT receptors, cytokines and growth factor 
expression and proliferation and also migration of the 
epidermal cells. They observed that the neurotensin 
did not affect the viability of keratinocytes, however, 
neurotensin and the expression levels of all recipients 
ZHUH VLJQL¿FDQWO\ UHGXFHG 1HXURWHQVLQ WUHDWPHQW
stimulated the expression of neurotensin receptor 
Figure 6- Dermal-epidermal skin substitute, immunostained, showing cell distribution. Red (Sytox, Invitrogen), green (Phalloidin, Invitrogen)
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2 (NTR2), whereas expression levels of neurotensin 
receptors 1 and 3 (NTR1, NTR3) did not change. 
Keratinocyte proliferation was not affected, but the 
migration of keratinocytes was reduced. Their results 
show that hyperglycemic conditions adversely affect 
the endogenous expression of neurotensin and its 
receptors, especially in keratinocytes NTR2 with 
important consequences for its function. This effect 
of neurotensin in hyperglycemic conditions has also 
been well studied in other cells such as macrophages, 
where it was observed that this neurotransmitter runs 
FHOOPLJUDWLRQSDWWHUQVDQGWKHLQÀDPPDWRU\UHVSRQVH
in wound healing18*LYHQWKHVH¿QGLQJV0RXUDHW
al.16,17 (2014) conducted two additional studies where 
neurotensin was added as a component to the dermo-
HSLGHUPDOVXEVWLWXWHVVSHFL¿FDOO\IRUWKHVFDIIROGRU
biomaterial in which cells are suspended. They tested 
in mediums of collagen and chitosan observing a 
UHGXFWLRQLQLQÀDPPDWRU\LQ¿OWUDWHVXSWRGD\DIWHU
implantation in rats with induced diabetes, and also 
an improvement in wound healing promoting cell 
migration and deposition of collagens I and III16,17. 
Future studies concerning the effect of NT are required 
in order to assess if in these neurotensin substitutes 
have an inhibitory proliferation role.
Fibrosis is a complication of chronic hyperglycemia 
involving the excessive proliferation of extracellular 
matrix (ECM) and its accumulation in various tissues 
and organs, the most prominent being microcirculation, 
kidney, heart, retina and wound healing. Chronic 
hyperglycemia affects the cells responsible for the 
production of collagen IV causing this accumulation4. 
Our results support this statement, as it showed 
LQFUHDVHG LPPXQRÀXRUHVFHQFH IRU DQWLFROODJHQ,9
DQG¿EUREODVWVRI WKHGHUPDOHSLGHUPDO VXEVWLWXWHV
generated from diabetic subjects (8.05) compared 
with healthy subjects (6.15). Berlanga-Acosta, et 
al.5 (2010) reported that under the high glucose load 
LPSRVHGE\GLDEHWHVVNLQDQGVNLQ¿EUREODVWVZHUH
disturbed in recreated in vitro clinical models showing 
DOWHUDWLRQV WR WKH QRUPDO SK\VLRORJ\ RI ¿EUREODVWV
as well as extracellular matrix secretion, therefore, 
it has been suggested that high concentrations of 
glucose is the major trigger of a cascade of molecular 
FKDQJHVWRVNLQ¿EUREODVWV,QRXUVWXG\FHOOFXOWXUHV
RIGLDEHWLFVXEMHFWVUHDFKHGDQFRQÀXHQFHLQD
shorter time (25.3 days) than healthy subjects (26.85 
days) suggesting a permanent effect of hyperglycemic 
conditions in cell physiology; however further study 
is needed.
Differences in the collagen production of diabetic 
subjects’ cells could suggest that diabetic substitutes 
might improve the healing of diabetic foot ulcers, 
however more research is needed to determine the 
clinical impact of the differences found. Additionally 
these substitutes may be used to test new drugs in 
an environment that is closer to that of real tissues.
Results of our study were measurable and 
TXDQWL¿DEOHLQWHQVLW\RIFROODJHQ,9DQGDQWLF\WRNHUDWLQ
5-14 in arbitrary fluorescence units) showing 
numerical variations in the amount of expression 
of both antibodies in both populations; diabetic and 
healthy subjects, suggesting differences in cellular 
function under this clinical condition and, with possible 
implications in the clinical application of the substitute. 
Also it is necessary to emphasize that the cells not 
only survived through the development process of 
the substitute, but also they were integrated in to 
the dermal matrix and secreted basal membrane 
VXSSRUWHGE\WKHSRVLWLYHH[SUHVVLRQRIWKHVSHFL¿F
markers CK5-14 and COL IV.
'HVSLWHWKHDERYHWKHVLJQL¿FDQFHRIWKHVH¿QGLQJV
is not yet known, further studies are needed to 
elucidate them. However this data may provide a basis 
to perfect/improve the development technique of the 
dermal-epidermal substitutes from the oral mucosa of 
diabetic patients and to answer the biological questions 
raised by it.
Within the constraints of our study, it is worth 
mentioning that no in vitro tests were performed to 
evaluate the functionality of the developed substitute, 
such as migration essays. In that matter, the next step 
would be in vivo and in vitro essays of functionality of 
these substitutes developed by this technique and the 
characterization proposed in this study. This will lead 
us to the future clinical application of these diabetic 
skin substitutes.
Conclusions
It is possible to develop dermal-epidermal 
substitutes from the isolation of the epidermal cells 
of oral mucosa from diabetic and healthy subjects 
using the air-liquid technique and its assessment by 
LPPXQRÀXRUHVFHQFHFKDUDFWHUL]LQJDQGTXDQWLI\LQJLWV
LQWHQVLW\LQDUELWUDU\ÀXRUHVFHQFHXQLWV$)8
Derma l -ep ide rma l  sk in  subs t i t u tes  o f 
diabetic subjects showed reduced keratinocyte 
GUZMÁN-URIBE D, ALVARADO-ESTRADA KN, PIERDANT-PÉREZ M, TORRES-ÁLVAREZ B, SÁNCHEZ-AGUILAR JM, ROSALES-IBÁÑEZ R
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LPPXQRÀXRUHVFHQFH LQWHQVLW\ ZKHQ FRPSDUHG WR
the substitutes from healthy subjects; while for 
¿EUREODVWVDQG&2/,9VXEVWLWXWHVRIGLDEHWLFVXEMHFWV
showed a greater intensity, with a higher AFU value. 
7KHVH¿QGLQJVVXJJHVWGLIIHUHQFHVLQFHOOXODUIXQFWLRQ
under this clinical condition; however more research 
is needed to determine the crosstalk which occurs 
between the components of these skin substitutes 
and the damaged tissues. The following long-term 
goal in this research is the clinical application of these 
substitutes; further in vivo animal studies  to evaluate 
functionality will be performed to continue with this 
matter.
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